Study finds HPV vaccine effective against precancerous cervical lesions
A new study published in The Lancet depicts that GlaxoSmithKline’s human papillomavirus (HPV) vaccine is highly effective at preventing precancerous cervical lesions that can lead to cervical cancer. The researchers said that the HPV-16/18 AS04-adjuvanted vaccine was as much as 98% effective against HPV-16/18, and between 37% and 54% effective against 12 other cancer-causing HPV types.
